Mohamed Ragab joins iTeos Therapeutics

Company
iTeos Therapeutics SA
Appointee name
Mohamed Ragab
Country

Belgium

Mohamed Ragab has been appointed vice president of corporate development at iTeos Therapeutics SA which is developing immunotherapies for cancer. Dr Ragab was most recently an executive at Bristol-Myers Squibb Co where he was involved in immuno-oncology transactions. Prior to this, he was global head of oncology partnering at Roche, and also held positions at Pfizer Inc, Ortho Biotech Inc and Schering-Plough (now Merck & Co Inc).

Dr Ragab holds a master’s degree in radiation oncology and a bachelor’s degree in medicine and surgery from Cairo University School of Medicine in Egypt.

iTeos Therapeutics announced the appointment on 29 June 2017.

Copyright 2017 Ever